EVOLUTION OF EASI RESPONSE WITH LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO- SEVERE ATOPIC DERMATITIS: POOLED RESULTS FROM TWO PHASE 3 TRIALS (ADVOCATE1 AND ADVOCATE2) AT WEEK 16

被引：0
|
作者：
Wollenberg, Andreas [1 ]
Warren, Richard B. [2 ]
Silverberg, Jonathan I. [3 ]
Guttman-Yassky, Emma [4 ]
Thaci, Diamant [5 ]
Irvine, Alan D. [6 ]
Gold, Linda Stein [7 ]
Blauvelt, Andrew [8 ]
Simpson, Eric L. [9 ]
Chu, Chia-Yu [10 ,11 ]
Liu, Zhuqing T. [12 ]
Lima, Renata Gontijo [12 ]
Pillai, Sreekumar [12 ]
Gil, Esther Garcia [13 ]
Seneschal, Julien [14 ,15 ]
机构：
[1] LMU Dept Dermatol & Allergol, Munich, Germany
[2] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester Nihr Biomed Res Ctr, Manchester, Lancs, England
[3] George Washington Univ, Dept Dermatol, Sch Med, Washington, DC USA
[4] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA
[5] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[6] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland
[7] Henry Ford Hlth Syst, Dermatol Clin Res, Detroit, MI USA
[8] Oregon Med Res Ctr, Portland, OR USA
[9] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR USA
[10] Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan
[11] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[12] Eli Lilly & Co, Indianapolis, IN USA
[13] Almirall SA, Barcelona, Spain
[14] Univ Bordeaux, Dept Dermatol, Bordeaux, France
[15] Hosp St Andre, Natl Reference Ctr Rare Skin Disorders, Dept Dermatol & Pediat Dermatol, Bordeaux, France
来源：
ACTA DERMATO-VENEREOLOGICA | 2023年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P10.9
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [41] Safety of baricitinib in patients with atopic dermatitis: Results of pooled data from two phase 3 monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and BREEZE-AD2)
    Reich, Kristian
    Lacour, Jean Philippe
    Costanzo, Antonio
    Brinker, Dennis R.
    Rueda, Maria Jose
    Nunes, Fabio P.
    Issa, Maher
    Paller, Amy
    Silverberg, Jonathan I.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB28 - AB28
  • [42] Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Food Allergy: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)
    Simpson, Eric L.
    Lacour, Jean-Philippe
    Silverberg, Jonathan I.
    Worm, Margitta
    Wollenberg, Andreas
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Akinlade, Bolanle
    Eckert, Laurent
    Gadkari, Abhijit
    Ardeleanu, Marius
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB131 - AB131
  • [43] Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials
    Eichenfield, Lawrence F.
    Boguniewicz, Mark
    Simpson, Eric L.
    Blauvelt, Andrew
    Gooderham, Melinda
    Lain, Edward
    Chu, David H.
    Higham, Robert C.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II10 - II11
  • [44] ONCE-DAILY ROFLUMILAST CREAM 0.15% FOR ATOPIC DERMATITIS: POOLED RESULTS: FROM INTEGUMENT-1/2 PHASE 3 TRIALS
    Eichenfield, L.
    Boguniewicz, M.
    Simpson, E.
    Blauvelt, A.
    Gooderham, M.
    Lain, E.
    Chu, D.
    Higham, R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S91 - S91
  • [45] Achieving a deep response on patient-reported outcomes with upadacitinib in patients with moderate-to-severe atopic dermatitis: results from three phase III trials
    Chovatiya, R.
    Schuttelaar, M. -L.
    Calimlim, B.
    Liu, Y.
    Takemoto, S.
    Staender, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E161 - E161
  • [46] Efficacy of tildrakizumab in patients with moderate to severe psoriasis according to disease duration: Pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials at week 28
    Thaci, Diamant
    Iversen, Lars
    Pau-Charles, Ignasi
    Schoenenberger Lopez, Andreu
    Blauvelt, Andrew
    Puig, Lluis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB160 - AB160
  • [47] Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
    Wollenberg, A.
    Blauvelt, A.
    Guttman-Yassky, E.
    Worm, M.
    Lynde, C.
    Lacour, J. -P.
    Spelman, L.
    Katoh, N.
    Saeki, H.
    Poulin, Y.
    Lesiak, A.
    Kircik, L.
    Cho, S. H.
    Herranz, P.
    Cork, M. J.
    Peris, K.
    Steffensen, L. A.
    Bang, B.
    Kuznetsova, A.
    Jensen, T. N.
    osterdal, M. L.
    Simpson, E. L.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 437 - 449
  • [48] Laboratory Safety From a 16-week Phase 3 Study of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis
    Pinter, Andreas
    Paller, Amy
    Wollenberg, Andreas
    Siegfried, Elaine C.
    Gonzalez, Mercedes E.
    Lockshin, Benjamin
    Khokhar, Faisal A.
    Chen, Zhen
    Gonzalez, Tayler
    Prescilla, Randy
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 88 - 89
  • [49] Laboratory safety from a 16-week phase 3 study of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis
    Paller, Amy S.
    Wollenberg, Andreas
    Siegfried, Elaine C.
    Gonzalez, Mercedes E.
    Lockshin, Benjamin
    Khokhar, Faisal A.
    Chen, Zhen
    Gonzalez, Tayler
    Prescilla, Randy
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [50] Efficacy of Baricitinib in Patients with Atopic Dermatitis and Atopic Comorbidities: Results of Pooled Data from 2 Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-week Trials (BREEZE-AD1 and BREEZE-AD2)
    Wollenberg, Andreas
    Boguniewicz, Mark
    Travers, Jeffrey
    Thyssen, Jacob
    Goldblum, Orin
    Ball, Susan
    Sun, Luna
    Chen, Sherry
    Silverberg, Jonathan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB190 - AB190
12345